Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cravacitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 known ✓ | P29597 | 17/20 | 1.00 |
| ▸ | JAK2 | O60674 | 7/20 | 1.00 |
| ▸ | JAK1 | P23458 | 4/20 | 0.89 |
| ▸ | STAT3 | P40763 | 2/20 | 0.89 |
| ▸ | JAK3 | P52333 | 2/20 | 0.89 |
| ▸ | STAT1 | P42224 | 1/20 | 0.89 |
| ▸ | BMPR2 | Q13873 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cravacitinib SCHEMBL21091048 | 1.00 | TYK2 (1.00) | TYK2JAK2JAK1STAT3JAK3 | |
| Deucravacitinib SCHEMBL29672335 | 0.95 | TYK2 (0.90) | TYK2JAK2JAK1STAT3JAK3 | |
| Deucravacitinib SCHEMBL29672338 | 0.94 | TYK2 (0.89) | TYK2JAK2JAK1STAT3JAK3 | |
| SCHEMBL23899841 | 0.94 | TYK2 (0.89) | TYK2JAK2JAK1STAT3JAK3 | |
| Deucravacitinib SCHEMBL20520348 | 0.94 | TYK2 (1.00) | TYK2JAK2JAK1STAT3JAK3 | |
| Deucravacitinib SCHEMBL29424395 | 0.94 | TYK2 (1.00) | TYK2JAK2JAK1STAT3JAK3 | |
| SCHEMBL23900241 | 0.93 | TYK2 (0.88) | TYK2JAK2JAK1STAT3JAK3 | |
| SCHEMBL23900225 | 0.93 | TYK2 (0.88) | TYK2JAK2JAK1STAT3JAK3 | |
| SCHEMBL23899768 | 0.93 | TYK2 (0.88) | TYK2JAK2JAK1STAT3JAK3 | |
| Deucravacitinib SCHEMBL30278579 | 0.93 | TYK2 (0.98) | TYK2JAK2JAK1STAT3JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO LTD (CN) | 2025-04-10 | — | — | US | disclosed |
| EP-4448514-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | Lynk Pharmaceuticals Co. Ltd. (CN) | 2024-10-23 | — | — | EP | disclosed |
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-04-18 | — | — | US | disclosed |
| WO-2023109954-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023108536-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | TYK2 1/4885JAK2 2/4885JAK1 3/4885 |
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | TYK2 1/4885JAK2 2/4885JAK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.